RS-5 / Resolute Science - LARVOL DELTA

A novel TAM-targeted therapeutic for rare and aggressive solid tumors (AACR 2026) - "A complete response was observed in a doxorubicin-resistant soft tissue sarcoma (STS) PDX model. RS-5 exhibits a favorable PK/PD profile; MTD and DRF are complete, and 4-week toxicology studies are underway.These preclinical results support broad clinical utility, particularly for TAM-rich tumors. A first-in-human dose-escalation study is planned for the summer of 2026."

First-in-human • IO biomarker • Brain Cancer • Gastric Cancer • Glioma • Melanoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Resolute Science Receives FDA Orphan Drug Designation for its Lead Therapeutic, RS-5, for Soft Tissue Sarcomas (PRWeb) - "This regulatory milestone underscores RS-5's therapeutic potential and supports the company's continued progress toward initiating first-in-human clinical trials in 2026."

New trial • Orphan drug • Soft Tissue Sarcoma